MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer

Overview of attention for article published in Clinical Cancer Research, February 2016

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 5 X users

Readers on

mendeley: 60 Mendeley

So far, Altmetric has seen 5 X posts from 5 X users, with an upper bound of 11,706 followers.

RT @libbyshope: MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer. https://t.co/OEqvuW5vL6

MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen resistance in high https://t.co/MZpyBd3lPF

MEK inhibitor, selumetininb, reverses antiestrogen resistance in high grade serous ovarian cancer. https://t.co/OEqvuW5vL6

MAPK activation predicts poor outcome and the MEK inhibitor, selumetininb, reverses antiestrogen… https://t.co/OhBBKmdw9i #breastcancer

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.